CapsoVision Announces Pricing of Initial Public Offering
CapsoVision (NASDAQ: CV), a commercial-stage medical technology company specializing in advanced imaging and AI-powered capsule endoscopy solutions, has announced the pricing of its initial public offering (IPO). The company is offering 5,500,000 shares of common stock at $5.00 per share.
Trading is set to commence on the Nasdaq Capital Market on July 2, 2025, under the ticker symbol "CV". The offering, expected to close on July 3, 2025, aims to raise approximately $27.5 million in gross proceeds before deducting underwriting costs and other expenses. The underwriters have a 30-day option to purchase up to 825,000 additional shares at the IPO price.
The Benchmark Company and Roth Capital Partners are serving as joint book-running managers for the offering, which will be conducted through a prospectus as part of an SEC-approved registration statement.
CapsoVision (NASDAQ: CV), un'azienda tecnologica medica in fase commerciale specializzata in soluzioni avanzate di imaging e capsula endoscopica potenziata da intelligenza artificiale, ha annunciato il prezzo della sua offerta pubblica iniziale (IPO). La societ脿 offre 5.500.000 azioni ordinarie al prezzo di 5,00 $ per azione.
Le negoziazioni inizieranno sul Nasdaq Capital Market il 2 luglio 2025, con il simbolo di borsa "CV". L'offerta, che si prevede si chiuder脿 il 3 luglio 2025, punta a raccogliere circa 27,5 milioni di dollari di proventi lordi prima delle spese di sottoscrizione e altri costi. I sottoscrittori hanno un'opzione di 30 giorni per acquistare fino a 825.000 azioni aggiuntive al prezzo dell'IPO.
The Benchmark Company e Roth Capital Partners agiscono come co-responsabili del collocamento per l'offerta, che sar脿 condotta tramite un prospetto nell'ambito di una dichiarazione di registrazione approvata dalla SEC.
CapsoVision (NASDAQ: CV), una empresa de tecnolog铆a m茅dica en etapa comercial especializada en soluciones avanzadas de imagen y c谩psula endosc贸pica impulsada por inteligencia artificial, ha anunciado el precio de su oferta p煤blica inicial (IPO). La compa帽铆a ofrece 5.500.000 acciones ordinarias a 5,00 $ por acci贸n.
La negociaci贸n comenzar谩 en el Nasdaq Capital Market el 2 de julio de 2025, bajo el s铆mbolo burs谩til "CV". Se espera que la oferta cierre el 3 de julio de 2025, con el objetivo de recaudar aproximadamente 27,5 millones de d贸lares en ingresos brutos antes de deducir costos de suscripci贸n y otros gastos. Los suscriptores tienen una opci贸n de 30 d铆as para comprar hasta 825.000 acciones adicionales al precio de la IPO.
The Benchmark Company y Roth Capital Partners act煤an como gestores conjuntos principales de la oferta, que se realizar谩 mediante un prospecto como parte de una declaraci贸n de registro aprobada por la SEC.
CapsoVision (NASDAQ: CV)電� 觳嫧 鞓侅儊 氚� AI 旮半皹 旌§姁 雮挫嫓瓴� 靻旊（靺橃潉 鞝勲鞙茧 頃橂姅 靸侅梾 雼硠 鞚橂 旮办垹 須岇偓搿�, 旮办梾瓿店皽(滨笔翱) 臧�瓴╈潉 氚滍憸頄堨姷雼堧嫟. 須岇偓電� 氤错喌欤� 5,500,000欤�毳� 欤茧嫻 5.00雼煬鞐� 鞝滉车頃╇媹雼�.
瓯半灅电� 2025雲� 7鞗� 2鞚� 雮橃姢雼� 旌愴敿韯� 毵堨紦鞐愳劀 "CV"霛茧姅 韹办护 鞁臣搿� 鞁滌瀾霅� 鞓堨爼鞛呺媹雼�. 鞚措矆 瓿惦電� 2025雲� 7鞗� 3鞚� 膦呺霅� 鞓堨爼鞚措┌, 鞚胳垬 牍勳毄 氚� 旮绊儉 牍勳毄鞚� 鞝滌櫢頃橁赴 鞝� 鞎� 2,750毵� 雼煬鞚� 齑濎垬鞚奠潉 氇╉憸搿� 頃╇媹雼�. 鞚胳垬雼潃 IPO 臧�瓴╈溂搿� 斓滊寑 825,000欤� 於旉皜 毵れ瀰 甓岆Μ毳� 30鞚缄皠 氤挫湢頃╇媹雼�.
The Benchmark Company鞕� Roth Capital Partners臧� 瓿惦彊 欤缄磤靷靹� 鞚措矆 瓿惦毳� 歆勴枆頃橂┌, SEC 鞀轨澑 霌彪靹滊鞚� 鞚茧秬鞚� 韴瀽靹る獏靹滊ゼ 韱淀暣 歆勴枆霅╇媹雼�.
CapsoVision (NASDAQ : CV), une entreprise technologique m茅dicale en phase commerciale sp茅cialis茅e dans l'imagerie avanc茅e et les solutions d'endoscopie par capsule aliment茅es par l'IA, a annonc茅 le prix de son offre publique initiale (IPO). La soci茅t茅 propose 5 500 000 actions ordinaires au prix de 5,00 $ par action.
La cotation d茅butera sur le Nasdaq Capital Market le 2 juillet 2025, sous le symbole "CV". L'offre, qui devrait se cl么turer le 3 juillet 2025, vise 脿 lever environ 27,5 millions de dollars de produit brut avant d茅duction des frais de souscription et autres d茅penses. Les souscripteurs disposent d'une option de 30 jours pour acheter jusqu'脿 825 000 actions suppl茅mentaires au prix de l'IPO.
The Benchmark Company et Roth Capital Partners agissent en tant que co-chefs de file pour cette offre, qui sera men茅e via un prospectus dans le cadre d'une d茅claration d'enregistrement approuv茅e par la SEC.
CapsoVision (NASDAQ: CV), ein medizinisches Technologieunternehmen in der kommerziellen Phase, das sich auf fortschrittliche Bildgebung und KI-gest眉tzte Kapselendoskopiel枚sungen spezialisiert hat, hat die Preisfestsetzung seines B枚rsengangs (IPO) bekannt gegeben. Das Unternehmen bietet 5.500.000 Stammaktien zum Preis von 5,00 USD pro Aktie an.
Der Handel soll am 2. Juli 2025 am Nasdaq Capital Market unter dem Tickersymbol "CV" beginnen. Das Angebot, das voraussichtlich am 3. Juli 2025 abgeschlossen wird, soll vor Abzug von Underwriting-Geb眉hren und anderen Kosten etwa 27,5 Millionen USD Bruttoerl枚s einbringen. Die Underwriter haben eine 30-t盲gige Option, bis zu 825.000 zus盲tzliche Aktien zum IPO-Preis zu erwerben.
The Benchmark Company und Roth Capital Partners fungieren als gemeinsame Bookrunner f眉r das Angebot, das 眉ber einen Prospekt im Rahmen einer von der SEC genehmigten Registrierung durchgef眉hrt wird.
- Expected to raise $27.5 million in gross proceeds from the IPO
- Listing on a major exchange (Nasdaq Capital Market)
- 30-day option for underwriters to purchase additional 825,000 shares indicates confidence in demand
- Relatively small IPO size may limit institutional investor interest
- Low share price of $5.00 could suggest limited market valuation
Insights
CapsoVision's $27.5M IPO brings a commercial-stage medical imaging company to Nasdaq at $5.00 per share.
CapsoVision has announced the pricing of its initial public offering on the Nasdaq Capital Market. The company is offering 5,500,000 shares of common stock at $5.00 per share, with trading expected to commence on July 2, 2025, under the ticker symbol "CV." The offering should generate
The IPO structure includes a standard 30-day option granted to underwriters to purchase up to an additional 825,000 shares at the initial offering price. This overallotment provision, commonly known as a "greenshoe option," allows underwriters to stabilize the stock price following the initial listing.
As a commercial-stage company focusing on advanced imaging and AI technologies for capsule endoscopy solutions, CapsoVision has positioned itself at the intersection of medical device technology and artificial intelligence. The mid-tier investment banks The Benchmark Company and Roth Capital Partners are serving as joint book-running managers, which is consistent with the offering size.
The successful registration with the SEC (declared effective on July 1) represents an important milestone in the company's development, providing access to public capital markets. While this offering size is relatively modest compared to larger medical technology IPOs, it potentially provides CapsoVision with additional capital to support its existing commercial operations.
SARATOGA, Calif., July 01, 2025 (GLOBE NEWSWIRE) -- CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company that develops advanced imaging and artificial intelligence (鈥淎I鈥�) technologies that are deployed in its capsule endoscopy solutions, today announced the pricing of its initial public offering of 5,500,000 shares of common stock at a public offering price of
CapsoVision has granted the underwriters a 30-day option to purchase up to an additional 825,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by the Company, are expected to be approximately
The Benchmark Company, LLC and Roth Capital Partners are acting as joint book-running managers for the offering.
A registration statement on Form S-1 relating to the shares was declared effective by the U.S. Securities and Exchange Commission (SEC) on July 1, 2025. The offering is being made only by means of a prospectus forming a part of such registration statement. Copies of the final prospectus, when available, may be obtained from The Benchmark Company, LLC, 150 East 58th Street, 17th Floor, New York, NY 10155, Attention: Prospectus Department, or by email at [email protected]
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CapsoVision
CapsoVision is a commercial-stage medical technology company focused on developing advanced imaging and AI-enabled solutions to transform the detection and diagnosis of gastrointestinal diseases. Its flagship product, CapsoCam Plus庐, is a wire-free, panoramic capsule endoscope that enables high-resolution visualization of the small bowel and supports cloud-based or direct capsule video retrieval. The Company鈥檚 next pipeline product, CapsoCam Colon, is designed to enable non-invasive colon imaging and polyp detection. With a proprietary platform targeted to expand across multiple GI indications, including esophageal and pancreatic disorders, CapsoVision is advancing a new era in capsule-based diagnostics. For more information on CapsoVision, please visit .
Forward-Looking Statements
This press release contains forward-looking statements, including statements related to the expected trading of CapsoVision鈥檚 common stock on the Nasdaq Capital Market and the anticipated closing of the offering. These forward-looking statements are based on the Company鈥檚 current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, market conditions, the satisfaction of customary closing conditions related to the initial public offering, and other risks described in the Company鈥檚 registration statement on Form S-1 filed with the SEC. Forward-looking statements speak only as of the date of this press release, and CapsoVision undertakes no obligation to update or revise these statements, except as required by law.
Investor Relations Contact
Leigh Salvo
New Street Investor Relations
Kevin Lundquist
Chief Financial Officer, CapsoVision, Inc.
[email protected]
Media Contact
Leslie Strickler and Paul Spicer
脢tre Communications
聽| (804) 240-0807
聽| (804) 503-9231
FAQ
What is the IPO price for CapsoVision (NASDAQ: CV) stock?
When will CapsoVision (CV) stock start trading on Nasdaq?
How much money is CapsoVision (CV) raising in its IPO?
Who are the underwriters for CapsoVision's IPO?
What does CapsoVision (CV) company do?
